Physician profile
Michael A Sciarrino
NPI 1639519200
$2,960.98
in general payments reported to CMS, 2019-2025
30 companies · $14.84 in 2025
The $14.84 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,483 · 2022: $1,150 · 2023: $297 · 2024: $15.51 · 2025: $14.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $457.24 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $298.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $292.66 | 2021-2022 | |
| Boston Scientific Corporation | $189.21 | 2021-2023 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.98 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $169.93 | 2021-2022 | |
| Amarin Pharma, INC. | $162.31 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $143.55 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $125.00 | 2023 | Rebyota |
| Abbvie INC. | $122.81 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $116.93 | 2022 | |
| Merck Sharp & Dohme LLC | $85.51 | 2021-2024 | Bridion |
| Bayer Healthcare Pharmaceuticals INC. | $85.42 | 2021-2022 | |
| Pfizer INC. | $77.79 | 2021-2022 | |
| Edwards Lifesciences Corporation | $63.99 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.05 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $46.77 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $39.89 | 2021 | |
| Esperion Therapeutics, INC. | $38.78 | 2021 | |
| Abiomed | $30.29 | 2022 | |
| Medtronic, INC. | $30.13 | 2021-2022 | |
| Genzyme Corporation | $24.27 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.08 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.71 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.51 | 2021 | |
| Akcea Therapeutics, INC. | $16.51 | 2021 | |
| Amryt Pharma Holdings LTD | $16.42 | 2021 | |
| Novo Nordisk INC | $15.26 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.84 | 2025 | Exparel |
| Arbor Pharmaceuticals, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sciarrino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.